C.R. Bard upgraded to Overweight from Neutral at JPMorgan JPMorgan upgraded C.R. Bard based on expectations for a resolution of the Gore patent litigation, a positive outcome in the LEVANT 2 trial, and higher earnings revisions. Price target raised to $116 from $110.
News For BCR From The Last 14 Days
Check below for free stories on BCR the last two weeks.